{"meshTags":["Melanoma","Antineoplastic Combined Chemotherapy Protocols","Signal Transduction","Mutation, Missense","Humans","Molecular Targeted Therapy","Feedback, Physiological","MAP Kinase Kinase Kinases","Proto-Oncogene Proteins B-raf","Randomized Controlled Trials as Topic"],"meshMinor":["Melanoma","Antineoplastic Combined Chemotherapy Protocols","Signal Transduction","Mutation, Missense","Humans","Molecular Targeted Therapy","Feedback, Physiological","MAP Kinase Kinase Kinases","Proto-Oncogene Proteins B-raf","Randomized Controlled Trials as Topic"],"genes":["RAF","MEK","RAF","MEK","RAF","ERK","MEK","RAF","ERK"],"publicationTypes":["Journal Article"],"abstract":"In BRAF V600E melanoma patients, RAF inhibitor treatment causes a MEK-inhibitor-sensitive, RAF-inhibitor-resistant adaptive reactivation of ERK signaling. In clinical trials combining MEK and RAF inhibitors, therapeutic efficacy was modestly enhanced, suggesting the utility of inhibiting feedback-reactivated pathways. Strategies for optimally inhibiting ERK signaling should be explored. ","title":"Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged.","pubmedId":"25517746"}